Nitroglycerin (also known as GTN), a nitric oxide (NO) signaling activator, and TH-302, a hypoxia-activated prodrug, in hypoxic cancer cells inhibits PD-L1 expression, decreases MDSCs and hypoxia-mediated cytotoxic T-cell death, overall, making cancer cells more susceptible to T cell-mediated cytotoxicity (162, 163). This evidence concerns the gene CD274 and cancer.